-
Add to Cart The item has been addedAb170728-1mgIbalizumab (anti-CD4) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab (anti-CD4) has the potential for HIV-1 infection research. Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb170728-5mgIbalizumab (anti-CD4) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab (anti-CD4) has the potential for HIV-1 infection research. Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb176053-100μgIcrucumab (anti-FLT1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab (anti-FLT1) has the potential for the research of advanced solid tumors.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg -
Add to Cart The item has been addedAb176424-100μgIdactamab (anti-SLC1A5) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab (anti-SLC1A5) can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5).Purity>95% -
Add to Cart The item has been addedAb176424-10mgIdactamab (anti-SLC1A5) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab (anti-SLC1A5) can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5).Purity>95% -
Add to Cart The item has been addedAb176424-1mgIdactamab (anti-SLC1A5) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab (anti-SLC1A5) can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5).Purity>95% -
Add to Cart The item has been addedAb176424-5mgIdactamab (anti-SLC1A5) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab (anti-SLC1A5) can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5).Purity>95% -
Add to Cart The item has been addedAb176429-100μgInotuzumab (anti-CD22) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab (anti-CD22) can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab (anti-CD22) can be used for the research of acute -
Add to Cart The item has been addedAb176429-10mgInotuzumab (anti-CD22) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab (anti-CD22) can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab (anti-CD22) can be used for the research of acute -
Add to Cart The item has been addedAb176429-1mgInotuzumab (anti-CD22) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab (anti-CD22) can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab (anti-CD22) can be used for the research of acute -
Add to Cart The item has been addedAb176429-5mgInotuzumab (anti-CD22) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab (anti-CD22) can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab (anti-CD22) can be used for the research of acute -
Add to Cart The item has been addedAb176451-100μgKWAR23 (anti-SIRPg) is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
